- Home
- PBYI vs IDE Comparison
PBYI vs IDE Comparison
Compare PBYI & IDE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- IDE
- Stock Information
- Founded
- PBYI 2010
- IDE 2010
- Country
- PBYI United States
- IDE United States
- Employees
- PBYI N/A
- IDE N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- IDE Finance/Investors Services
- Sector
- PBYI Health Care
- IDE Finance
- Exchange
- PBYI Nasdaq
- IDE Nasdaq
- Market Cap
- PBYI 138.4M
- IDE N/A
- IPO Year
- PBYI N/A
- IDE N/A
- Fundamental
- Price
- PBYI $3.07
- IDE $10.79
- Analyst Decision
- PBYI Strong Buy
- IDE
- Analyst Count
- PBYI 1
- IDE 0
- Target Price
- PBYI $7.00
- IDE N/A
- AVG Volume (30 Days)
- PBYI 275.3K
- IDE 33.5K
- Earning Date
- PBYI 05-08-2025
- IDE 01-01-0001
- Dividend Yield
- PBYI N/A
- IDE 8.83%
- EPS Growth
- PBYI 37.78
- IDE N/A
- EPS
- PBYI 0.62
- IDE N/A
- Revenue
- PBYI $230,468,000.00
- IDE N/A
- Revenue This Year
- PBYI N/A
- IDE N/A
- Revenue Next Year
- PBYI N/A
- IDE N/A
- P/E Ratio
- PBYI $4.92
- IDE N/A
- Revenue Growth
- PBYI N/A
- IDE N/A
- 52 Week Low
- PBYI $2.23
- IDE $8.61
- 52 Week High
- PBYI $5.20
- IDE $10.46
- Technical
- Relative Strength Index (RSI)
- PBYI 51.76
- IDE 62.74
- Support Level
- PBYI $2.88
- IDE $10.40
- Resistance Level
- PBYI $3.14
- IDE $10.84
- Average True Range (ATR)
- PBYI 0.14
- IDE 0.19
- MACD
- PBYI 0.01
- IDE 0.06
- Stochastic Oscillator
- PBYI 64.00
- IDE 94.74
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.